The United States is facing an increase in human infections by drug-resistant bacteria. One such bacteria, called New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales, is ...
EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results